

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>4</sup> :</b> <b>C12N 15/00, 1/20, C12P 19/56</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 89/11532</b> <b>(43) International Publication Date:</b> 30 November 1989 (30.11.89)
<b>(21) International Application Number:</b> PCT/EP89/00588 <b>(22) International Filing Date:</b> 26 May 1989 (26.05.89) <b>(30) Priority data:</b> 8812697.4 27 May 1988 (27.05.88) GB <b>(71) Applicant (for all designated States except US):</b> FARMITALIA CARLO ERBA S.R.L. [IT/IT]; Via Carlo Imbonati, 24, I-20159 Milan (IT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> CARUSO, Marinella [IT/IT]; Via Ozanam, 4, I-Milan (IT). COLOMBO, Anna, Luisa [IT/IT]; Via Elba, 14, I-Milan (IT). GAROFANO, Luisa [IT/IT]; Via Ettore Fieramosca, 29, I-20052 Monza (IT). TORTI, Francesca [IT/IT]; Corso Garibaldi, 70, I-Milan (IT). <b>(74) Agents:</b> WOODS, Geoffrey, Corlett et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5EU (GB).		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), SU, US.  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ISOLATION AND CHARACTERISATION OF GENES RESISTANT TO ANTHRACYCLINE ANTIBIOTICS  <b>(57) Abstract</b>  Doxorubicin resistance can be conferred on a host by transforming the host with a recombinant vector comprising a DNA having the configuration of restriction sites shown in Figure 1 or 2 of the accompanying drawings or a restriction fragment derived therefrom containing a gene coding for doxorubicin resistance.		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IT	Italy	RO	Romania
BJ	Benin	JP	Japan	SD	Sudan
BR	Brazil	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

-1-

ISOLATION AND CHARACTERISATION OF GENES RESISTANT  
TO ANTHRACYCLINE ANTIBIOTICS

This invention relates to DNA fragments comprising genes conferring resistance to anthracycline antibiotics, to recombinant vectors comprising such DNA fragments and to hosts transformed with the vectors.

5           The anthracyclines of the daunorubicin group, such as doxorubicin, carminomycin and aclavinomycin, are among the most widely employed agents in antitumoral therapy. They are polyketides produced by various strains of Streptomyces (S. peucetius, S. coeruleorubidus,  
10 S. galilaeus, S. griseus, S. griseoruber, S. viridochromogenes and S. bifurcus).

Doxorubicin is only produced by S. peucetius var. caesius. The type strain S. peucetius var. caesius IMRU 3920 (hereinafter abbreviated to "S. peucetius 3920") is  
15 publically available and is described in US-A-3 590 028. S. peucetius 3920 has been deposited at the Institute of Microbiology of the Rutgers University, US, receiving the index number IMRU 3920. This strain and its mutants obtained by classical mutagenic treatments are resistant to  
20 high levels of doxorubicin.

The study of the mechanisms involved in the resistance to these substances is crucial for two main reasons:

-2-

- a) There are many examples in which the genes involved in the biosynthesis of secondary metabolites are all clustered together with at least one resistance gene: for example oxytetracycline (Rhodes P M, Hunter I S, Friend E J and Warren M, 1984, Trans Biochem Soc 12, 586-587), erythromycin (Stanzak R, Matsushima P, Baltz R H and Rao R N, Biotechnology vol 4, March 1986, 229-232), tylosin (Fayerman J T, Biotechnology vol 4, Sept 1986, 786-789) and tetracenomycin (Motamedi H, Hutchinson C R, Proc Natl Acad Sci USA, vol 84, 4445-4449, 1987). Cloning the biosynthetic genes can be useful with a view to altering pathways to produce different molecules or to overcome bottlenecks present in the biosynthesis routes thus augmenting the productivity of the strain.
- b) The resistance itself can be implied in the regulatory mechanisms so that changing the resistance levels (i.e. augmenting the gene dosage) the productivity of the strain can be improved. This is an old idea usually performed via the classical methods of mutagenesis and random screening, but renewed by the utilisation of rDNA methods (Craveri R and Davies J E, The Journal of Antibiotics, Jan 1986, 128-135).

We have now isolated two DNA segments which incorporate doxorubicin resistance genes. Accordingly, the present invention provides DNA having the configuration of restriction sites shown in Figure 1 or 2 of the accompanying drawings or a restriction fragment derived

-3-

therefrom containing a gene coding for doxorubicin resistance. For convenience, the DNA segments shown in Figures 1 and 2 are called here insert DNA. The invention also provides:

- 5                   - recombinant vectors which are capable of transforming a host cell and which contain an insert DNA or a restriction fragment derived therefrom containing a doxorubicin resistance gene; and
- host cells transformed with such vectors.

10                   In more detail, in the accompanying drawings:

                  Figure 1 is the restriction map analysis of a first DNA of the invention. This is an insert in recombinant plasmid FICE 1 (Rec 1). The insert has Sau3AI ends and was inserted into the BglII site of pIJ702. One

15 BglII site was reconstituted after ligation.

                  Figure 2 is the restriction map analysis of a second DNA of the invention. This is an insert in recombinant plasmid FICE 2 (Rec 2). The insert has Sau3AI ends and was inserted into the BglII site of pIJ702. One

20 BglII site was reconstituted after ligation.

                  The maps shown in Figures 1 and 2 do not necessarily provide an exhaustive listing of all restriction sites present in each DNA segment. However, the reported sites are sufficient for an unambiguous

25 recognition of the segments.

-4-

The insert DNAs and restriction fragments of the invention contain a gene coding for doxorubicin resistance. For such a gene to be expressed, the DNA may carry its own transcription control sequence and, in particular, its own  
5 promoter which is operably connected to the gene and which is recognised by a host cell RNA polymerase. Alternatively, the insert DNA or restriction fragment may be ligated to another transcription control sequence in the correct fashion or cloned into a vector at a restriction  
10 site appropriately located neighbouring a transcription control sequence in the vector.

An insert DNA or restriction fragment carrying a doxorubicin resistance gene may be cloned into a recombinant DNA cloning vector. Any autonomously  
15 replicating and/or integrating agent comprising a DNA molecule to which one or more additional DNA segments can be added may be used. Typically, however, the vector is a plasmid. A preferred plasmid is the high copy number plasmid pIJ702 (Katz et al, J Gen Microbiol 1983 129  
20 2703-2714). Any suitable technique may be used to insert the insert DNA or restriction fragment thereof into the vector. Insertion can be achieved by ligating the DNA into a linearised vector at an appropriate restriction site. For this, direct combination of sticky ends or homopolymer  
25 tailing or the use of a linker or adapter molecule may be employed.

-5-

The recombinant vector is used to transform a suitable host cell, typically cells that would benefit from being able to exhibit doxorubicin resistance. The host cells may be ones which are doxorubicin-sensitive, i.e. cannot grow in the presence of doxorubicin or ones which are doxorubicin-resistant but would benefit from greater resistance to doxorubicin. The host may be a microorganism. Strains of S. peucetius, more particularly S. peucetius var. caesius, which produce doxorubicin and other strains of Streptomyces which produce anthracyclines may therefore be transformed. Resistance, or greater resistance, to doxorubicin may enable more doxorubicin to be produced by cells of such a strain. Tolerance of greater concentrations of doxorubicin may be achieved.

Transformants of strains of S. peucetius are typically obtained by protoplast transformation. Doxorubicin can thus be obtained by culturing a transformed strain of S. peucetius and recovering the doxorubicin thus-produced.

The insert DNAs are obtained from the genomic DNA of S. peucetius M76. S. peucetius M76 is a mutant of S. peucetius 3920 which is able to convert daunorubicin to doxorubicin at high levels. S. peucetius M76 was deposited at the Deutsche Sammlung von Mikroorganismen (DSM), Federal Republic of Germany on 11 May 1988 under accession number D.S.M. 4592. A strain derived therefrom from S. peucetius M76 may also be used, which typically will also be able to

-6-

convert daunorubicin to doxorubicin. Insert DNAs may therefore be obtained by:

(a) preparing a library of the genomic DNA of S peucetius M76 or a strain derived therefrom;

5 (b) screening the library for doxorubicin resistance;

(c) obtaining an insert DNA from a recombinant vector which forms part of the library and which has been screened as positive for doxorubicin resistance; and

10 (d) optionally, obtaining from the insert DNA a restriction fragment which contains a gene coding for doxorubicin resistance.

The library may be prepared in step (a) by partially digesting the genomic DNA of S peucetius M76 or a  
15 strain derived therefrom. The restriction enzyme MboI is preferably used. The fragments thus obtained can be size-fractionated. Fragments of from 4 to 6 Kb in size are preferred. These fragments are ligated into a linearised vector such as pIJ702. Host cells are transformed with the  
20 ligation mixture. Typically, the host cells are doxorubicin-sensitive, for example sensitive to 50 mcg or less or, preferably 30 mcg or less of doxorubicin per ml. For example, S lividans TK 23 protoplasts may be transformed.

25 In step (b), the transformants thus-obtained are screened for doxorubicin resistance. Clones doxorubicin-resistant are identified by growth in a medium containing



-7-

dox rubicin. Such clones are isolated and recombinant vectors contained therein are extracted. On digestion of the recombinant vectors with suitable restriction enzymes in step (c), the S. peucetius M76 DNA inserted into each  
5 vector may be identified, sized and mapped. In this way, it may be checked that the vector contains an insert DNA of the invention.

Further, two or more overlapping inserts may be isolated which are wholly or partly embraced within the DNA  
10 of the invention. These may be fused together by cleavage at a common restriction site and subsequent ligation to obtain a DNA of the invention, pared in length using appropriate restriction enzymes if necessary. Restriction fragments of an insert DNA which contains a gene encoding  
15 for doxorubicin resistance may be obtained in step (d) also by cleaving an insert DNA with an appropriate restriction enzyme.

Finally, DNA of the invention may be mutated in a way which does not affect its ability to confer doxorubicin  
20 resistance. This can be achieved via site-directed mutagenesis for example. Such mutated DNA also forms part of the invention.

The following Example illustrates the invention. In the Example  $Ts^R$ ,  $Doxo^R$  and  $Doxo^S$  denote the  
25 thiostrepton-resistant, the doxorubicin-resistant and the doxorubicin-sensitive phenotypes respectively.

-8-

EXAMPLE1. Materials and MethodsBacterial strains and plasmids:

Streptomyces peucetius M76, a filamentous streptomycete  
5 producing daunorubicin and doxorubicin and resistant to  
doxorubicin (MIC 250 mcg/ml), and some biosynthetic mutants  
sensitive to doxorubicin; S. lividans TK 23 sensitive to  
doxorubicin.

Plasmid pIJ702 a high copy number was obtained  
10 from the John Innes Culture Collection, Norwich, GB.

Media and Buffers

TSB contained 30 g of tryptic soy broth (DIFCO)  
per litre of distilled water; YEME contained 5 g of yeast  
extract (DIFCO), 10 g of malt extract (DIFCO), 340 g of  
15 sucrose, 5 mM  $MgCl_2 \cdot 6H_2O$  and variable glycine  
concentrations per litre of distilled water.

The regeneration medium R2YE was as described by  
Chater K F, Hopwood D A , Kieser T and Thompson C J (1982)  
"Gene cloning in Streptomyces", 69-95 in P H Hofschneider  
20 and W Goebbel (ed) "Gene Cloning in Organisms other than  
E. coli", Springer-Verlag, Berlin. The medium was prepared  
with the following composition per litre:

-9-

sucrose	- 103 g	trace elements mix	- 2 ml
2.5% K <sub>2</sub> SO <sub>4</sub>	- 10 ml	0.5% KH <sub>2</sub> PO <sub>4</sub>	- 10 ml
MgCl <sub>2</sub> .6H <sub>2</sub> O	- 10.1 g	1M CaCl <sub>2</sub>	- 20 ml
glucose	- 10 g	proline	- 3 g
5 casaminoacids	- 0.1 g	0.25M TES pH 7.2	- 100 ml
agar	- 22 g	10% yeast extract	- 50 ml

Medium P was as described by Baltz R H, J Gen Microbiol 107: 93-102 (1978).

Streptomycetes were maintained on solid medium described in US-A-3 590 028, Example 2.

Growth Conditions: for liquid cultures both Streptomyces species were grown in 50 ml of YEME + TSB (1:1) at 28°C on a rotary shaker at 280 rpm. The growth medium was inoculated with homogenised mycelia.

15 Homogenisation was obtained by vortexing mycelia in a tube containing glass beads.

#### Protoplast transformation

Mycelia from 35 ml of liquid culture (supplemented with 0.5% glycine) were recovered by centrifugation (10 min, 1500 x g), washed twice with 10.3% sucrose, resuspended in 10 ml of P medium containing 1 mg/ml of lysozyme (SIGMA) and incubated for 60 minutes at 30°C with reciprocal shaking (280 rpm). After protoplast formation the suspension was filtered through cotton, washed once with medium P and resuspended in 1 ml of medium P. Usually 10<sup>8</sup> protoplasts were obtained.

-10-

For each transformation 200 ul of medium P containing about  $2 \times 10^7$  protoplasts were mixed with 10 ul of the desired amount of DNA in TE (Tris-HCl 10 mM, EDTA 1 mM pH 8.0), and with 800 ul of 25% polyethylene glycol (PEG) 1000 in medium P. 1 Minute after the addition of PEG solution, transformation was terminated by the addition of 5 ml of medium P. Protoplasts were pelleted by centrifugation, resuspended in 1 ml of P and plated on R2YE. After incubation for 24 hours at 28°C transformants were selected by flooding the plates with 3 ml soft NA (8 g of DIFCO nutrient broth and 5 g of agar per litre) containing the appropriate antibiotic. The number of transformants was about  $1 \times 10^4$  -  $1 \times 10^7$  per mcg of DNA, according to the strains utilised.

15        Isolation of plasmid and genomic DNA

Isolation of plasmid and genomic DNA from streptomycetes was performed using techniques described by Hepwood D A et al (1985) "Genetic Manipulation of Streptomyces - A Laboratory Manual" The John Innes Foundation.

20        Preparation of S. peucetius M76 genomic library

All restriction enzymes, calf thymus alkaline phosphatase and T4 ligase were obtained from BRL (Bethesda, MD) and used according to the manufacturer's instructions.

25    S. peucetius M76 genomic DNA was partially digested with MboI, and fragments ranging between 4 and 6 Kb in size recovered by electroelution from agarose gel. These

-11-

fragments wer ligated to pIJ702 linearised with BglII and phosphatase treated. The ligation mixture was used to transform S lividans TK 23 protoplasts sensitive to 30 mcg/ml of doxorubicin.

5

## 2. Results

### Cloning of DNA fragments which confer resistance to doxorubicin in sensitive Streptomyces strains

Partially MboI digested S. peucetius M76 genomic DNA was inserted into the BglII site of pIJ702. The  
10 ligation mix was used to transform S lividans TK 23 protoplasts. Transformants were selected for Thiostrepton resistance and white colour, indicating insertional inactivation of the melanin gene of pIJ702.

Thiostrepton-resistant white colonies were then  
15 screened for resistance to doxorubicin (100 mcg/ml). They were plated on R2YE medium, incubated at 28°C for 24 hours with 3 ml of soft NA containing 500 mcg/ml of doxorubicin; two clones Ts<sup>R</sup> and Doxo<sup>R</sup> were thus identified.

Extraction of plasmid DNA from these two clones  
20 revealed the presence of inserts of 5.7 kb and 4.4 kb in length. The two recombinant plasmids, named respectively FICE 1 and FICE 2, were again used to transform S lividans TK 23 protoplasts. In both cases transformation showed that the Doxo<sup>R</sup> character is conferred with high efficiency  
25 along with the Ts<sup>R</sup> one.

-12-

Expression of the Doxo<sup>R</sup> character in *S. peucetius*  
mutants Doxo<sup>S</sup>

The two recombinant plasmids were then introduced into some derivative mutants of *S. peucetius* M76 which are  
5 Doxo<sup>S</sup> (MIC 50 ug/ml). The transformants showed complementation of the Doxo<sup>S</sup> character. They could grow on doxorubicin 1500 ug/ml presenting a resistance to doxorubicin level higher than the parental strain *S. peucetius* M76, donor of the cloned genes (MIC 250  
10 mcg/ml). The increased level of resistance in the transformants might be explained by the high copy number of the recombinant plasmids (pIJ101 replicon, Katz et al 1983).

Restriction enzyme analysis of the cloned  
15 fragments

As the phenotype conferred by the two cloned fragments was the same, we investigated if there were one or two distinct functions able to confer the Doxo<sup>R</sup> character. Figures 1 and 2 show the restriction maps of  
20 the *S. peucetius* M76-derived inserts of FICE 1 and FICE 2. Most of each map is derived from the sizes of fragments generated by single and double digests using different combinations of enzymes. The interval lengths between adjacent sites come from direct measurements of the  
25 relevant fragments in appropriate double or single digests.

-13-

There is no obvious correspondence between the maps of the two cloned fragments, suggesting that the resistance is conferred by two distinct genes.

- 14 -

CLAIMS

1. A DNA having the configuration of restriction sites shown in Figure 1 or 2 of the accompanying drawings or a restriction fragment derived therefrom containing a gene coding for doxorubicin resistance.
- 5        2. A recombinant vector comprising a DNA sequence as defined in claim 1.
3. A vector according to claim 2, which is a plasmid.
4. A vector according to claim 3, wherein the DNA  
10 sequence is inserted in the plasmid pIJ702.
5. A host transformed with a vector as defined in claim 2.
6. A host according to claim 5 which is a microorganism which produces anthracyclines.
- 15       7. A host according to claim 5, which is a strain of S. peucetius.
8. A process for obtaining a DNA sequence as defined in claim 1, which process comprises:
  - (a) preparing a library of the genomic DNA of  
20 S. peucetius M76 (D.S.M. 4592) or a strain derived therefrom;
  - (b) screening the library for doxorubicin resistance;
  - (c) obtaining an insert DNA from a recombinant vector which forms part of the library and which has been  
25 screened positive for doxorubicin resistance; and





- 15 -

(d) optionally, obtaining from the insert DNA a restriction fragment which contains a gene coding for doxorubicin resistance.

9. A process for the preparation of a recombinant  
5 vector as defined in claim 2, which process comprises cloning a DNA sequence as defined in claim 1 into a vector.

10. A process for the preparation of doxorubicin, which process comprises culturing a strain of S. peucetius as claimed in claim 5 and recovering the doxorubicin  
10 thus-produced.

1/1

*Fig.1.**Fig.2.*

# INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 89/00588

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : C 12 N 15/00, C 12 N 1/20, C 12 P 19/56														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">IPC<sup>4</sup></td> <td style="padding: 5px;">C 12 N, C 12 P</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup></div>			Classification System	Classification Symbols	IPC <sup>4</sup>	C 12 N, C 12 P								
Classification System	Classification Symbols													
IPC <sup>4</sup>	C 12 N, C 12 P													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category <sup>9</sup></th> <th style="border-bottom: 1px solid black;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 10%; border-bottom: 1px solid black;">Relevant to Claim No. <sup>13</sup></th> </tr> <tr> <td style="border-right: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">           Experientia, vol. 38, 1982            Birkhäuser-Verlag            (Basel, CH)            N. Crespi-Perellino et al.: "Bio-synthetic relationships among daunorubicin, doxorubicin and 13-dihydro-daunorubicin in Streptomyces peucetius" pages 1455-1456            see the whole article            --         </td> <td style="border-right: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1-10</td> </tr> <tr> <td style="border-right: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">           Abstracts of the Annual Meeting of the American Society for Microbiology, 88th Annual Meeting, 8-13 May 1988, Miami Beach, Florida, American Soc. For Microbiology (US)            K.J. Stutzman-Engwall et al.: "Cloning and identification of genes involved in daunorubicin production in Streptomyces peucetius", see page 261, abstract 0-2            --         </td> <td style="border-right: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1-10</td> </tr> <tr> <td style="border-right: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">           194th American Chemical Society National Meeting, 30 August - 4 september 1987, New Orleans, Louisiana, US            --         </td> <td style="border-right: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1-10</td> </tr> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	Y	Experientia, vol. 38, 1982 Birkhäuser-Verlag (Basel, CH) N. Crespi-Perellino et al.: "Bio-synthetic relationships among daunorubicin, doxorubicin and 13-dihydro-daunorubicin in Streptomyces peucetius" pages 1455-1456 see the whole article --	1-10	Y	Abstracts of the Annual Meeting of the American Society for Microbiology, 88th Annual Meeting, 8-13 May 1988, Miami Beach, Florida, American Soc. For Microbiology (US) K.J. Stutzman-Engwall et al.: "Cloning and identification of genes involved in daunorubicin production in Streptomyces peucetius", see page 261, abstract 0-2 --	1-10	A	194th American Chemical Society National Meeting, 30 August - 4 september 1987, New Orleans, Louisiana, US --	1-10
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
Y	Experientia, vol. 38, 1982 Birkhäuser-Verlag (Basel, CH) N. Crespi-Perellino et al.: "Bio-synthetic relationships among daunorubicin, doxorubicin and 13-dihydro-daunorubicin in Streptomyces peucetius" pages 1455-1456 see the whole article --	1-10												
Y	Abstracts of the Annual Meeting of the American Society for Microbiology, 88th Annual Meeting, 8-13 May 1988, Miami Beach, Florida, American Soc. For Microbiology (US) K.J. Stutzman-Engwall et al.: "Cloning and identification of genes involved in daunorubicin production in Streptomyces peucetius", see page 261, abstract 0-2 --	1-10												
A	194th American Chemical Society National Meeting, 30 August - 4 september 1987, New Orleans, Louisiana, US --	1-10												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top;"> <sup>10</sup> Special categories of cited documents:            "A" document defining the general state of the art which is not considered to be of particular relevance            "E" earlier document but published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td style="width: 50%; vertical-align: top;">           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step            "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.            "A" document member of the same patent family         </td> </tr> </table>			<sup>10</sup> Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family										
<sup>10</sup> Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family													
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of the Actual Completion of the International Search            24th August 1989         </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of Mailing of this International Search Report            28. 09. 89         </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">           International Searching Authority            EUROPEAN PATENT OFFICE         </td> <td style="border-bottom: 1px solid black; padding: 5px;">           Signature of Authorized Officer  <div style="text-align: right; font-family: cursive; font-size: 1.2em;">T.K. WILLIS</div> </td> </tr> </table>			Date of the Actual Completion of the International Search 24th August 1989	Date of Mailing of this International Search Report 28. 09. 89	International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer <div style="text-align: right; font-family: cursive; font-size: 1.2em;">T.K. WILLIS</div>								
Date of the Actual Completion of the International Search 24th August 1989	Date of Mailing of this International Search Report 28. 09. 89													
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer <div style="text-align: right; font-family: cursive; font-size: 1.2em;">T.K. WILLIS</div>													

III. D CUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
	<p>Abstr. Pap. Am. Chem. Soc. 194(0) 1987, Medi 5 (US) C.R. Hutchinson et al.: "Possibilities for the development of new antitumor drugs by genetic engineering of anthracycline", see abstract</p> <p>--</p>	
A	<p>Nature, vol. 325, 26 February 1987, F. Malpartida et al.: "Homology between Streptomyces genes coding for synthesis of different polyketides used to clone antibiotic biosynthetic genes" pages 818-821, see figures 1,2; page 819, left- hand column, last paragraph</p> <p>--</p>	1-5,9
A	<p>EP, A, 0173327 (MEIJA SEIKA KAISHA LTD) 5 March 1986, see page 6, line 33 - page 7, line 5; example 2 particularly page 19, lines 28-36</p> <p>--</p>	2-5,8-10
A	<p>EP, A, 0204549 (ELI LILLY AND CO.) 10 December 1986, see example 7; page 3, line 5 - page 4, line 26; table III; page 28, lines 1-25</p> <p>--</p>	1-10
A	<p>Mol. Gen. Genet., vol. 205, 1986, Springer-Verlag T. Murakami et al.: "The bialaphos biosynthetic genes of Streptomyces hygroscopicus: Molecular cloning and characterization of the gene cluster", pages 42-50, see summary; page 45, right-hand column, page 48, right-hand column, paragraph 3</p> <p>--</p>	1-10
A	<p>Chemical Abstracts, vol. 104, 1986, (Columbus, Ohio, US), J.S. Lampel et al.: "Transformation and transfection of anthracycline- producing streptomycetes", voir page 178, résumé 103498p &amp; Appl. Environ. Microbiol. 1986, 51(1), 126-31</p> <p>--</p>	6,7

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	<p>Journal of Bacteriology, vol. 151, no. 2, (US)  C.J. Thompson et al.: "Biochemical characterization of resistance determinants cloned from antibiotic-producing streptomycetes", pages 678-685,  see page 684, right-hand column, last paragraph</p>	8-10
A	<p>The Journal of Antibiotics, vol. 59, no. 1, January 1986  R. Cramer et al.: "Increased production of aminoglycosides associated with amplified antibiotic resistance genes", page 128,  see summary</p> <p>-----</p>	8-10

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 8900588

SA 28931

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on 22/09/89  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0173327	05-03-86	JP-A- 61058589	25-03-86
EP-A- 0204549	- 10-12-86	AU-A- 5836786	11-12-86
		JP-A- 61285991	16-12-86